BioSpace News Archive

Immunicom, Inc., a clinical stage biotech, shared preliminary data from its metastatic triple-negative breast cancer (mTNBC) clinical trial with its novel breakthrough Immunopheresis® therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021.

ClexBio, a start-up developing bioengineered human blood vessels for transplant, has secured US$2.2m in seed funding from private investors and governmental grants.

Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC)

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2021 financial and operating results after the market closes on Tuesday, August 10, 2021, and will host a conference call on the same day at 2:00 p.m. PT/5:00 p.m. ET.

AB Science SA announces publication of a peer-reviewed article titled ‘Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2’ in the journal Science.

OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has raised ¥800 million in Series B financing led by The University of Tokyo Edge Capital Partners (UTEC) with participation of ITOCHU Technology Ventures (ITV).

Dr. Tyler Jones is a graduate of Brigham Young University in Provo, UT, and graduated medical school at Ross University School of Medicine.

Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Paul Mann was appointed to the Board of Directors.